Addressing systemic barriers and implementing policies can reduce disparities in healthcare access and promote equity in treatment. Increasing awareness and education among healthcare providers ...

A Registrational Phase 2 clinical trial has been initiated in Japan for patients with PSMA-positive metastatic castration-resistant prostate ...

The PROSTATE-IQ trial uses the ArteraAI Prostate Test to personalize treatment for prostate cancer recurrence post-prostatectomy, potentially reducing hormone therapy use. The trial stratifies ...

After skin cancer, prostate cancer is the most common cancer among men in the U.S., and 20% to 30% of men who beat it once will face a recurrence within five years. A new treatment, known as salvage ...

A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that oxybutynin, a drug often used to ...

Many patients with high-risk biochemically recurrent prostate cancer based on PSA doubling time are unidentified in clinical practice. Clinicians unaware of patients’ PSA doubling time (PSADT) at ...

Prostate cancer is one of the most common cancers in the world. While many prostate cancers grow slowly and remain localized, other types are aggressive and spread quickly. That's why Dr. Carlos ...

Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, ...

In recent times, men are facing various health issues, with prostate cancer being one of the most prevalent. This type of cancer ranks among the most common forms affecting the male population.

While prostate cancer recurrence is a major cause of death in patients receiving localized treatment, there are other significant causes of mortality. While prostate cancer progression or recurrence ...